• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>CNS spectrums >Pharmacotherapy of schizophrenia: toward a metabolomic-based approach
【24h】

Pharmacotherapy of schizophrenia: toward a metabolomic-based approach

机译：精神分裂症的药物治疗：朝向基于代谢的方法

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Approximately 20%–30% of schizophrenia patients are resistant to current standard pharmacotherapies. Recent schizophrenia research aims to identify specific pathophysiological abnormalities and novel targets in the disease, with the goals of identifying at-risk individuals, facilitating diagnosis, prompting early and personalized interventions, and helping predict response to treatment. Metabolomics involves the systematic study of the profile of biochemical alterations early in the course of a given disorder. Major aspects of the schizophrenia metabolome have been characterized, uncovering potential selective biomarkers for the disease that may change how the disorder is diagnosed, and how patients are stratified and treated. This review focuses on the most common metabolomic fingerprints of the different pathways involved in the pathophysiology of schizophrenia, and the potential development of novel metabolomic-related pharmacotherapies for improved treatment of schizophrenia and other related idiopathic psychotic disorders.
机译：大约20％-30％的精神分裂症患者对当前的标准药物治疗有抵抗力。最近的精神分裂症研究旨在识别该疾病的特定病理生理异常和新型靶标，鉴定风险的人，促进诊断，提示早期和个性化干预措施，以及帮助预测对待疗法。代谢组虫涉及在给定疾病过程中早期对生物化学改变的概况的系统研究。已经表征了精神分裂症代谢物的主要方面，揭示了可能改变疾病如何诊断疾病的疾病的潜在选择性生物标志物，以及如何分层和治疗患者。本综述侧重于涉及精神分裂症病理生理学的不同途径的最常见的代谢指纹，以及新型代谢组相关药物治疗的潜在发展，用于改善精神分裂症和其他相关特发性精神病患者的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号